Paget's Disease

Published Date : Oct 2023
Category : Chronic Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Paget’s Disease: A Unique and Rare Bone Condition

“Unleashing the Market Insights of Paget’s Disease: Creating a Unique Strategies”

Paget’s disease is a prevalent condition people are facing worldwide and has become a major public health problem. Paget’s disease is more common in individuals of Anglo-Saxon descent and those living in specific geographic locations, such as the United States, England, Australia, New Zealand, and Western Europe. However, it is unusual in Scandinavia, China, Japan, and India.

Paget's disease of bone is a chronic skeletal disease. A process known as remodeling eliminates old bone fragments and replaces them with new, fresh bone in healthy bone. Paget's disease causes this process to shift out of balance, resulting in irregularly formed, fragile, and brittle new bone.

Many individuals with Paget's disease have no symptoms and are unaware of their condition until X-rays are performed for another reason. The common symptoms of Paget’s disease are bone pain, improper bone formation, broken bones, fatigue, weakness, loss of appetite, abdominal pain, and constipation.

However, other indications and symptoms of the disease frequently arise as the condition advances. These may include more bending of the afflicted limbs, a waddling gait, joint discomfort, and inflammation (arthritis), fractures of affected bones, and muscular and sensory abnormalities.

In addition to that, hearing loss can occur in up to 50% of those who have skull involvement. Other signs and symptoms that arise include loss of eyesight and hydrocephalus, a disease in which an excess of cerebrospinal fluid (CSF) in the skull creates pressure on the brain structures.

Moreover, Paget's disease has an unknown cause. According to the researchers, the disorder's etiology might be multifactorial. According to research findings, Paget's disease is caused by a "slow virus" infection of the bone, which exists for many years before symptoms manifest. There is a familial history of the disease in ~15–30% of cases.

However, numerous genes that predispose people to Paget's disease have been found by researchers (genetic predisposition). The sequestosome 1 gene, the VCP gene, and the TNFRSFIIA gene, which codes for the RANK protein, are genes linked to this condition. It's unclear exactly how these genes contribute to the disorder's development.

Moreover, Paget's disease does not often proceed to Paget's sarcoma, a kind of bone cancer. When this happens, symptoms include acute and unremitting pain in the Paget's disease-afflicted region. Only approximately 1% of people with Paget's disease develop Paget's sarcoma. These patients are often above 70 years old.

Paget's disease of bone (PDB) is the second most common metabolic bone disease in the world, with a prevalence ranging from ~1.5% to 8.3%.

The prevalence of Paget's disease of the bone differs by nation. In several European nations, Paget's disease of the bone is more frequent. Paget's disease of the bone affects around 1% of the population in the United States.

A number of factors influence the market for Paget's disease, including its high prevalence and the lack of early diagnosis tools. Other factors contributing to the sector's growth include the rising frequency of medical disorders globally and the difficulties in pinpointing the fundamental causes of Paget's disease development.

It is critical to diagnose Paget's disease early because it does not show symptoms early. The discovery of curative treatments that are less expensive and have fewer adverse effects is also critical in Paget’s disease landscape. This opens up several opportunities for market actors to enter this area and earn new business value. 

DiseaseLandscape Insights (DLI) helps all healthcare stakeholders. By giving information on Paget's disease market, knowledgeable decisions in medical technology, therapies, and diagnostic procedures, and information on how different new technological breakthroughs are influencing the illness market and encouraging more growth.

DiseaseLandscape Insights assists all industry players in choosing the best domain for them to develop and build a strong business in the treatment as well as diagnostic field of Paget’s disease.

Diagnostic Analysis of Paget’s Disease

“Diagnostic Advancements: Empowering the Better Health”

The diagnosis of Paget’s disease is initiated with physical examination and medical history of patients. The following tests are performed to come up with an accurate diagnosis of Paget’s disease.

  • X-rays

X-rays provide pictures of dense materials like bone. An X-ray is frequently used to diagnose Paget's disease. A Paget's bone is often bigger and denser than a regular bone.

  • Laboratory Examinations

A serum alkaline phosphatase blood test is also done to confirm the diagnosis. Alkaline phosphatase levels are typically higher in people with Paget's disease, reflecting the rapid bone turnover rate.

  • Bone Scan

A bone scan assists in determining which bones are affected. A very small quantity of radioactive dye is injected into a vein during this procedure. A unique camera is then used to detect locations of the skeleton with enhanced radioactive material absorption. These hotspots represent places where bone turnover is higher than usual. Except when the condition has been established for a long time and has burnt out, Paget's disease nearly always appears heated on a bone scan.

  • Biopsy

A biopsy is necessary to confirm Paget's disease or to rule out other diseases. A biopsy involves removing a tiny sample of the damaged bone and examining it under a microscope. The technique is done under local anesthetic with a needle or as a minor open surgery.

Diagnostic tests are often conducted in public laboratories that are given with highly skilled staff and the required, typically costly equipment. There is a lot of competition in the market for Paget's disease diagnostics, and a large number of industrial suppliers serve this market.

Industry corporations have the potential to develop novel low-cost, accurate, and quick bone imaging tests and biopsy procedures using the use of technology and in-depth study. Development and progress of diagnostic procedures will raise the standard for important stakeholders.

Disease Landscape Insights provides data on current market participants and their products for achieving a better knowledge of market dynamics, and it also helps industry leaders with the development of different diagnostic kits and the use of new technologies to improve current diagnostic procedures. DLI services help companies stay competitive, manage the industry's complicated expectations, and improve public health by improving the detection of Paget's disease.

The market participants and their products that are revolutionizing Paget's disease diagnostic category are included in the table below.

Diagnostic Market Player


Siemens Healthineers


Roche Diagnostics

Elecsys Intact PTH Assay

Beckman Coulter

ACCESS PTH Intact Assay

Ortho Clinical Diagnostics





Treatment Analysis of Paget’s Disease

“Establishing Innovative Treatment Approaches: Generating Health Benefits”

The treatment option available for Paget’s disease helps to reduce symptoms and future complications. Patients with Paget's disease are treated using four main approaches: analgesic pain management, pharmacological therapy using either bisphosphonates or calcitonins, physical therapy focusing primarily on improving muscle strength to help control some types of pain, and surgical intervention.

  • Pharmacological Treatment

Pharmacological treatment includes various drugs like bisphosphonates and calcitonin which help to manage the condition of Paget’s disease and control the complications.


Bisphosphonates inhibit or reduce the resorption of osteoclasts in the bone. They accomplish this in two ways: directly, by impeding the recruitment and functionality of osteoclasts; and indirectly, by inducing osteoblasts to generate an inhibitor that prevents the development of osteoclasts. The mechanisms of action of these medications are now reasonably known, and knowledge of the variations across bisphosphonates has improved.

The recommended course of therapy for Paget's disease is Zoledronic Acid (Reclast). Intravenous administration consists of a 15-minute infusion of 5 mg. To lower the risk of low blood calcium following infusions, patients should get 1000 units of vitamin D and 1500 mg of calcium daily for two weeks before treatment. People with low blood calcium, vitamin D insufficiency, or impaired renal function should not use zoledronic acid (Reclast).

One or two 60 mg infusions of Pamidronate disodium suppress a moderate form of Paget's disease, but several 60–90 mg infusions of Pamidronate given weekly or twice a week are necessary for a more severe expression of the disease. Testing for serum alkaline phosphatase should take place two to three months following the administration of the recommended dosage of infusion.

In order to reduce hypocalcemia, a typical adverse effect of this medication, patients should take oral calcium and vitamin D supplements. Patients who have low blood calcium levels or a vitamin D deficiency should not be treated with Paidronate disodium.


Salmon calcitonin injections under the skin served as the first commercially successful treatment for Paget's disease. It has been demonstrated that salmon calcitonin improves some neurological problems, reduces warmth over damaged bones, lowers increased indices of bone turnover by fifty percent, and speeds up the healing of lytic lesions. It also lessens sensations of bone pain. These days, patients who cannot take bisphosphonates are the main ones who can utilize it.

  • Pain Management: Analgesics

The anti-osteoclast therapy typically reduces pain that is directly related to Paget's disease. Bone deformities, rheumatic conditions, or neurological issues all cause pain. In this instance, in addition to the primary pagetic medication selected, acetaminophen, non-steroidal anti-inflammatory medicines (NSAIDS), or cox-2 inhibitors are beneficial for the management of Pagetic pain.

  • Surgery

Various orthopedic interventions are required in patients suffering from Paget’s disease. The fixing of a complete fracture by surgery, realignment of bones specifically the knee through tibial osteotomy, and replacement of bones in the hip region or knee region by joint arthroplasty are some of the kinds of surgeries and the conditions involved in Paget’s disease patient.

The Paget's disease treatment area offers several opportunities for enterprises. Participants in the market focus on the production of various cost-effective therapeutic products, as well as the redevelopment of current medicines via the implementation of new technologies to enhance patient health while increasing business profit.

Disease Landscape Insights (DLI) conducts extensive research on the treatment of Paget's disease to keep stakeholders one step above the competition. DLI provides updates on treatment options, new drugs, and treatments, as well as goods and services. DLI additionally undertakes extensive research on competitors in the treatment sector and helps to create unique treatment options for improved patient health.

The below table lists the names of treatment market players in Paget’s disease sector and their innovative products that are improving the health of patients.

Treatment Market Players




Deeb Agro Chemicals Private Limited

Etidronate (Didronel)

Sanofi Chimie

Tiludronate (Skelid)

Procter & Gamble Pharmaceuticals, Inc.

Risedronate (Actonel)

Novartis Pharmaceuticals

Zoledronic acid (Reclast)

Biozenta Lifescience

Pamidronate disodium (Aredia)

Novartis Pharmaceuticals

Zoledronic acid (Zometa)


Denosumab (Xgeva)

Merck & Co.

Alendronate (Fosamax)

BioCryst Pharmaceuticals


Alexion Pharmaceuticals

Asfotase alfa (Strensiq)


Market Trends

“Exploring The Trending Market of Paget’s Disease: Constructing the Better Business Framework”

It is best to review industry publications, medical journals, and news sources to remain up to speed on the newest market trends and advancements associated with Paget's disease, as well as keep a watch on announcements from pharmaceutical firms and research organizations. Working with healthcare experts and patient advocacy groups also gives useful insights into the present state of Paget's disease.

However, bisphosphonates have long been used to treat Paget's disease. The developments of more effective or safer bisphosphonates, as well as alternative therapies, are some market developments in this field. Key players should consider these opportunities for their business establishment.

Moreover, in the market for rare conditions, the cost of therapy is a significant consideration. Pricing and reimbursement strategies will need to be considered by pharmaceutical firms and healthcare systems. Market players should consider the cost factor to develop novel treatments and expand their business.

Bone disease research and development contributes to the development of more effective and focused therapies for Paget's disease. Conducting focused research for effective treatments is the way for stakeholders to expand their business all over the world and build a strong economy for the company.

Competitive Analysis

“Reviewing The Competitor’s Growth: Making Informed Decision”

However, a lot of multinational industries are focused on discovering novel product categories and expanding the use of technology to improve existing operations to boost their level of competition. Companies are also focused on approaches to increase their product offering, most commonly through collaborations and acquiring regulatory approval for new drugs, medical improvements, and technology.

In addition, alliances and cooperative efforts among pharmaceutical corporations, diagnostic markets, and research institutes are redirecting the field by promoting information sharing, expediting development procedures, and expanding market penetration into international markets. It is anticipated that competition will be fierce and tough as the industry evolves further.

Due to the condition's rarity, competition in the Paget's disease industry is relatively low, but it is intense among businesses engaged in the larger rare disease and bone health industries. Acquisitions, partnerships, and cooperative efforts with academic institutions and patient advocacy groups are improving the ability of a company to develop medicines for Paget's disease.

Moreover, companies like Novartis, Amgen, Merck and Co., NPS Pharmaceuticals, Alexion Pharmaceuticals, and BioCryst Pharmaceuticals are involved in the research and development of drugs for bone-related diseases including Paget’s disease. The expertise and strategies are creating a unique approach in the Paget’s disease market and they are setting the standards for new key players.

Competitive analysis is an essential aspect of healthcare strategy development. DLI assists in analyzing and grasping competitors' strengths and weaknesses in the field of healthcare to make informed decisions and get a competitive edge. Companies that invest in stated competition analysis are better positioned to adapt to industry developments and successfully satisfy their patients' and consumers' requests.


Disease Landscape Insights helps the industry by advancing patient recruitment, clinical trial protocols, and regulatory compliance for new medicines. It contributes to the healthcare sector's objective of developing novel solutions that enhance commercial potential in Paget's disease treatment portfolio.

Disease Landscape Insight intends to assess the burden caused by the Paget disease condition by examining a variety of factors that suggest future market trends for pharmaceutical companies conducting research and development for Paget disease diagnostic tools and medications.

Disease Landscape Insight publishes a variety of market studies and business insights developed by highly qualified and informed industry analysts. Our research publications vary a wide range of disease categories, including infectious disease, chronic disease, genetic disease, autoimmune disease, mental health problems, and environmental disease.

All in all, DLI supports all the market players to choose the right path for their businesses and put a stronger foothold in the Paget disease domain.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape